CA2919076C - Stabilization of fc-containing polypeptides - Google Patents
Stabilization of fc-containing polypeptides Download PDFInfo
- Publication number
- CA2919076C CA2919076C CA2919076A CA2919076A CA2919076C CA 2919076 C CA2919076 C CA 2919076C CA 2919076 A CA2919076 A CA 2919076A CA 2919076 A CA2919076 A CA 2919076A CA 2919076 C CA2919076 C CA 2919076C
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- region
- antibody
- amino acid
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361860800P | 2013-07-31 | 2013-07-31 | |
| US61/860,800 | 2013-07-31 | ||
| PCT/US2014/048908 WO2015017548A2 (en) | 2013-07-31 | 2014-07-30 | Stabilization of fc-containing polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2919076A1 CA2919076A1 (en) | 2015-02-05 |
| CA2919076C true CA2919076C (en) | 2024-01-30 |
Family
ID=52432568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2919076A Active CA2919076C (en) | 2013-07-31 | 2014-07-30 | Stabilization of fc-containing polypeptides |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20160193295A1 (enExample) |
| EP (1) | EP3027647A4 (enExample) |
| JP (2) | JP2016526909A (enExample) |
| KR (3) | KR20250152665A (enExample) |
| CN (2) | CN105658664A (enExample) |
| AU (3) | AU2014296215A1 (enExample) |
| BR (1) | BR112016002219A2 (enExample) |
| CA (1) | CA2919076C (enExample) |
| CL (1) | CL2016000232A1 (enExample) |
| EA (1) | EA035319B1 (enExample) |
| HK (1) | HK1224203A1 (enExample) |
| IL (1) | IL243690B (enExample) |
| MX (2) | MX2016001165A (enExample) |
| SG (1) | SG11201600734YA (enExample) |
| WO (1) | WO2015017548A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| CA2899170C (en) | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| JP6704358B2 (ja) | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害を治療するための組成物および使用方法 |
| CN106687128B (zh) * | 2014-10-31 | 2022-05-10 | Ngm生物制药有限公司 | 用于治疗代谢病症的组合物和方法 |
| EP3233920B1 (en) | 2014-12-19 | 2020-08-26 | Alkermes, Inc. | Single chain fc fusion proteins |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| CA3025162A1 (en) | 2016-05-26 | 2017-11-30 | Qilu Puget Sound Biotherapeutics Corporation | Mixtures of antibodies |
| WO2018005226A2 (en) * | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| CN110325205B (zh) * | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| CN110234355B (zh) * | 2017-02-01 | 2021-11-09 | 浙江时迈药业有限公司 | 单体人IgG1 Fc和双特异性抗体 |
| US20200157172A1 (en) * | 2017-07-07 | 2020-05-21 | HANMl PHARM. CO., LTD. | Novel therapeutic enzyme fusion protein and use thereof |
| AU2018318440A1 (en) | 2017-08-15 | 2020-02-13 | Kindred Biosciences, Inc. | IgG Fc variants for veterinary use |
| CN107540748B (zh) * | 2017-09-15 | 2020-07-14 | 北京伟杰信生物科技有限公司 | 长效重组猪fsh融合蛋白及其制备方法与应用 |
| EP3708661A4 (en) | 2017-12-22 | 2021-12-01 | Hanmi Pharm. Co., Ltd. | THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| CN109021109A (zh) * | 2018-07-20 | 2018-12-18 | 上海交通大学 | 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法 |
| BR112021002032A2 (pt) | 2018-08-03 | 2021-07-20 | Amgen Research (Munich) Gmbh | construtos de anticorpos para cldn18.2 e cd3 |
| KR102148405B1 (ko) * | 2018-09-19 | 2020-08-27 | 주식회사 바이오앱 | 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법 |
| KR102200773B1 (ko) * | 2018-09-19 | 2021-01-12 | 주식회사 바이오앱 | 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물 |
| WO2020167957A1 (en) * | 2019-02-12 | 2020-08-20 | Board Of Regents, The University Of Texas System | High affinity engineered t-cell receptors targeting cmv infected cells |
| CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| US20220227888A1 (en) | 2019-06-07 | 2022-07-21 | Amgen Inc. | Bispecific binding constructs with selectively cleavable linkers |
| US20220348632A1 (en) * | 2019-09-18 | 2022-11-03 | Novartis Ag | Nkg2d fusion proteins and uses thereof |
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| KR102899743B1 (ko) * | 2019-12-11 | 2025-12-12 | 주식회사 엘지화학 | O-글리코실화 가능한 폴리펩타이드 영역 및 gdf15를 포함하는 융합 폴리펩타이드 |
| US20230093169A1 (en) | 2020-01-22 | 2023-03-23 | Amgen Research (Munch) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
| JP7481856B2 (ja) | 2020-02-25 | 2024-05-13 | シスメックス株式会社 | 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法 |
| CN111285936A (zh) * | 2020-03-11 | 2020-06-16 | 北京双赢科创生物科技有限公司 | 靶向肿瘤的酸性敏感纳米肽段及其应用 |
| TW202200615A (zh) | 2020-03-12 | 2022-01-01 | 美商安進公司 | 用於治療和預防患者的crs之方法 |
| WO2021236638A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| CN116096736B (zh) * | 2020-08-14 | 2026-07-10 | 武汉友微生物技术有限公司 | 新型冠状病毒rbd融合蛋白 |
| JP7627413B2 (ja) * | 2020-08-21 | 2025-02-06 | ファチアブジェン インコーポレイテッド | ガンマ定常領域（Ｃγ１）とイプシロン定常領域（Ｃε２－４）とが融合された重鎖及び軽鎖の定常領域からなる抗体断片及びその用途 |
| CN114426974B (zh) * | 2020-10-29 | 2023-11-21 | 洛阳普泰生物技术有限公司 | 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段 |
| CN117120479A (zh) * | 2020-11-02 | 2023-11-24 | 阿特拉斯公司 | Sap fc融合蛋白及其使用方法 |
| BR112023008317A2 (pt) * | 2020-11-02 | 2024-02-06 | Attralus Inc | Proteínas de fusão sap fc e métodos de uso |
| EP4240770A1 (en) | 2020-11-06 | 2023-09-13 | Amgen Research (Munich) GmbH | Polypeptide constructs selectively binding to cldn6 and cd3 |
| WO2022120286A1 (en) * | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| US20240350588A1 (en) * | 2021-08-24 | 2024-10-24 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and use thereof |
| CN116064562A (zh) * | 2022-10-28 | 2023-05-05 | 江南大学 | 玉米赤霉烯酮的真核表达单链抗体以及全长抗体的制备方法以及用途 |
| CN116284455B (zh) * | 2023-04-17 | 2024-10-11 | 北京康乐卫士生物技术股份有限公司 | 一种带状疱疹病毒疫苗的嵌合抗原及其应用 |
| EP4762084A1 (de) * | 2023-08-17 | 2026-06-24 | Gottfried Wilhelm Leibniz Universität Hannover (LUH) | Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern |
| WO2025162460A1 (zh) * | 2024-02-04 | 2025-08-07 | 南通壹宸生物医药科技有限公司 | 一种轭合化合物及其制备和应用 |
| CN118344462B (zh) * | 2024-06-18 | 2024-11-08 | 苏州易合医药有限公司 | 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品 |
| CN119613573B (zh) * | 2025-02-14 | 2025-05-30 | 浙江大学 | 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途 |
| CN119735654B (zh) * | 2025-02-27 | 2025-07-01 | 浙江海隆生物科技股份有限公司 | 一种牛副流感病毒的亚单位hn蛋白制备方法和应用 |
| CN120623322B (zh) * | 2025-08-14 | 2025-12-05 | 成都蓉生药业有限责任公司 | 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用 |
| CN120923615B (zh) * | 2025-08-15 | 2026-07-03 | 成都蓉生药业有限责任公司 | 一种人IgG1 Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG1 Fc变体的制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| EP0979281B1 (en) * | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) * | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| WO2006028936A2 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101866623B1 (ko) * | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| EP2504360B1 (en) * | 2009-11-23 | 2018-08-15 | Amgen Inc. | Monomeric antibody fc |
| PT3156420T (pt) | 2010-12-06 | 2019-05-27 | Seattle Genetics Inc | Anticorpos humanizados a liv-1 e seu uso para tratar o cancro |
-
2014
- 2014-07-30 EP EP14832297.7A patent/EP3027647A4/en active Pending
- 2014-07-30 WO PCT/US2014/048908 patent/WO2015017548A2/en not_active Ceased
- 2014-07-30 CN CN201480046222.5A patent/CN105658664A/zh active Pending
- 2014-07-30 MX MX2016001165A patent/MX2016001165A/es unknown
- 2014-07-30 BR BR112016002219A patent/BR112016002219A2/pt not_active Application Discontinuation
- 2014-07-30 CA CA2919076A patent/CA2919076C/en active Active
- 2014-07-30 US US14/909,431 patent/US20160193295A1/en not_active Abandoned
- 2014-07-30 SG SG11201600734YA patent/SG11201600734YA/en unknown
- 2014-07-30 HK HK16112553.6A patent/HK1224203A1/zh unknown
- 2014-07-30 IL IL243690A patent/IL243690B/en unknown
- 2014-07-30 CN CN202610132063.5A patent/CN121930334A/zh active Pending
- 2014-07-30 KR KR1020257032842A patent/KR20250152665A/ko active Pending
- 2014-07-30 EA EA201690299A patent/EA035319B1/ru not_active IP Right Cessation
- 2014-07-30 KR KR1020237032656A patent/KR20230141929A/ko not_active Ceased
- 2014-07-30 JP JP2016531860A patent/JP2016526909A/ja active Pending
- 2014-07-30 KR KR1020167004786A patent/KR20160034404A/ko not_active Ceased
- 2014-07-30 AU AU2014296215A patent/AU2014296215A1/en not_active Abandoned
-
2016
- 2016-01-27 MX MX2022008013A patent/MX2022008013A/es unknown
- 2016-01-28 CL CL2016000232A patent/CL2016000232A1/es unknown
-
2019
- 2019-03-08 US US16/297,494 patent/US20190192628A1/en active Pending
-
2020
- 2020-01-17 AU AU2020200329A patent/AU2020200329A1/en not_active Abandoned
- 2020-09-25 JP JP2020160475A patent/JP7344858B2/ja active Active
-
2022
- 2022-02-22 AU AU2022201204A patent/AU2022201204B2/en active Active
-
2025
- 2025-01-17 US US19/030,935 patent/US20250325631A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016001165A (es) | 2016-06-29 |
| AU2022201204B2 (en) | 2025-01-02 |
| AU2020200329A1 (en) | 2020-02-06 |
| CN105658664A (zh) | 2016-06-08 |
| EP3027647A2 (en) | 2016-06-08 |
| IL243690B (en) | 2022-09-01 |
| JP2016526909A (ja) | 2016-09-08 |
| HK1224203A1 (zh) | 2017-08-18 |
| KR20230141929A (ko) | 2023-10-10 |
| EA201690299A1 (ru) | 2016-11-30 |
| WO2015017548A2 (en) | 2015-02-05 |
| KR20160034404A (ko) | 2016-03-29 |
| KR20250152665A (ko) | 2025-10-23 |
| WO2015017548A3 (en) | 2015-11-05 |
| US20160193295A1 (en) | 2016-07-07 |
| MX2022008013A (es) | 2022-07-27 |
| EA035319B1 (ru) | 2020-05-27 |
| US20190192628A1 (en) | 2019-06-27 |
| AU2022201204A1 (en) | 2022-03-17 |
| EP3027647A4 (en) | 2017-01-04 |
| CN121930334A (zh) | 2026-04-28 |
| CA2919076A1 (en) | 2015-02-05 |
| CL2016000232A1 (es) | 2016-09-02 |
| IL243690A0 (en) | 2016-04-21 |
| JP7344858B2 (ja) | 2023-09-14 |
| BR112016002219A2 (pt) | 2017-09-12 |
| SG11201600734YA (en) | 2016-02-26 |
| AU2014296215A1 (en) | 2016-02-11 |
| US20250325631A1 (en) | 2025-10-23 |
| JP2021019598A (ja) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022201204B2 (en) | Stabilization of Fc-containing polypeptides | |
| CN104508133B (zh) | 用于产生单体和多聚体分子的方法及其用途 | |
| EP2504360B1 (en) | Monomeric antibody fc | |
| EP3576789B1 (en) | MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES | |
| US20230235024A1 (en) | Fc-Containing Molecules Exhibiting Predictable, Consistent, and Reproducible Glycoform Profiles | |
| TW201102087A (en) | Bispecific antigen binding proteins | |
| US12054552B2 (en) | Humanized anti-IL-1R3 antibody and methods of use | |
| IL298610A (en) | Antibodies that bind to cd3- and folr1 | |
| KR20240099460A (ko) | Cd20-pd1 결합 분자 및 이의 사용 방법 | |
| HK40037872A (en) | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190717 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250627 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250627 |